MUMBAI (Reuters) - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.
via Reuters: Health News Read More Here..
No comments:
Post a Comment